Endogenous endothelin maintains coronary artery tone by endothelin type a receptor stimulation in patients undergoing coronary arteriography

Heart

Volumn 84, Issue 2, 2000, Pages 176-182

  Kyriakides, Z S ^a   Kremastinos, D T ^a   Bofilis, E ^a   Tousoulis, D ^a   Antoniadis, A ^a   Webb, D J ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiography; Arteries; Blood flow; Coronary circulation; Endothelins

Indexed keywords

ENDOTHELIN A RECEPTOR;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTERY TONE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; HUMAN; PRIORITY JOURNAL;

EID: 0033867351     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.84.2.176     Document Type: Article

References (35)

1. Yanagisawa M, Kurihawa H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15.
2. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-7.
3. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci 1993;84:485-500.
4. Webb DJ, Haynes WG. Endothelin come of age. Lancet 1993;342:1439-40.
5. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-4.
6. Haynes WG, Ferro CJ, O'Kane KPJ, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93:1860-70.
7. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-6.
8. Webb DJ, Monge JC, Rabelink TJ, et al. Endothelin: new discoveries and rapid progress in the clinic. Trends Physiol Sci 1998;19:5-8.
9. Hamsen A, Franco-Cereceda A, Matran R, et al. Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue. Eur J Pharmacol 1990;191:319-28.
10. Grover GJ, Sleph PG, Fox M, et al. Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts. J Pharmacol Exp Ther 1992;263;1074-82.
11. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993;27:1613-18.
12. Cannan CR, Burnett JC, Brandt RR, et al. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation 1995;92:3312-17.
13. Pernow J, Kaijser L, Lundberg JM, et al. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996;94:2077-82.
14. Bassan M, Ganz W, Marcus HS, et al. The effect of intracoronary injection of contrast medium upon coronary blood flow. Circulation 1975;51:442-5.
15. Wsineski JA, Gertz EW, Neeze R, et al. Myocardial metabolic alterations after contrast angiography. Am J Cardiol 1982;50:239-45.
16. Ferro CJ, Haynes WG, Hand MF, et al. The vascular endothelin and nitric oxide systems in essential hypertension [abstract]. J Hypertens 1996;14:S50.
17. de Berrazueta JR, Bhagat K, Vallance P, et al. Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol 1997;44:569-71.
18. Ihara M, Noguchi K, Saeki T, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992;50:247-55.
19. Reiber JHC, Serruys PW, Koouman C, et al. Assessment of short-, medium- and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 1985;71:280-8.
20. Austen WG, Edwards JE, Frye RL, et al. Reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975;51:7-37.
21. Doucette JW, Corl DP, Payne HP, et al. Validation of a Doppler guidewire for intravascular measurement of coronary artery flow velocity. Circulation 1992;85:1899-911.
22. Takeuchi M, Nohtomi Y, Kuroiwa A. Does coronary flow reserve assessed by blood flow velocity analysis reflect absolute coronary flow reserve? Cathet Cardiovasc Diagn 1996;38:251-4.
23. Plumpton C, Ferro CJ, Haynes WG, et al. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment indices by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996;119:311-14.
24. Lefroy DC, Crake T, Uren NG, et al. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993;88: 43-54.
25. Feldman R, Pepine C, Conti R. Magnitude of dilatation of large and small coronary arteries by nitroglycerin. Circulation 1981;64:324-33.
26. Hermann HC, Rosenthal AD, Davis CA. Cardiovascular effects of intracoronary atrial natriuretic peptide administration in man. Am Heart J 1990;120:308-15.
27. Chew CYC, Brown BG, Singh BN, et al. Effects of verapamil on coronary hemodynamic function and vasomotility relative to its mechanism of antianginal action. Am J Cardiol 1983;51:699-705.
28. Simonetti I, Caterina R, Michelassi C, et al. Coronary vasodilation by nitrates is not mediated by prostaglandin system: a quantitative cineangiographic study. J Am Coll Cardiol 1986;8:1263-70.
29. Zuberbuhler RC, Bohr DF. Responses of coronary smooth muscle to catecholamines. Circ Res 1965;16:431-40.
30. Schnaar RL, Sparks HV. Response of large and small coronary arteries to nitroglycerin, NaNO and adenosine. Am J Physiol 1972;223:223-8.
31. Bax WA, VandenBrink AM, Saxena PR. Endothelin-B receptors do not contribute to ET-1 induced vasoconstriction in human isolated coronary arteries [abstract]. Fifth International Conference on Endothelin, Kyoto, Japan, 1997.
32. Rigel DF, Lappe RW. Differential responsiveness of conduit and resistance coronary arteries to endothelin A and B receptor stimulation in anesthetized dogs. J Cardiovasc Pharmacol 1993;22(suppl 8):S243-7.
33. Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998;98: 2235-40.
34. Haynes WG, Webb DJ. Endothelium-dependent modulation of responses to endothelin-1 in human hand veins. Clin Sci 1993;84:427-33.
35. Yokokawa K, Tahara H, Kohno M, et al. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest 1993;92: 2080-5.